Objective: To investigate the possible mechanisms of the antiatherosclerotic effects of the angiotensin-converting enzyme (ACE) 0 inhibitor, fosinopril, in apolipoprotein (apo) E deficient mice. Methods: Apo E deficient (E ) mice at the age of 8 weeks received either placebo or a high dose (25 mg / kg / d) of fosinopril supplemented in their drinking water. Results: After 12 weeks of treatment, fosinopril reduced the aortic lesion size by 70%, compared with the placebo group. At this dosage, fosinopril significantly reduced blood pressure from 9362 mmHg before treatment to 7062 mmHg at the end of the treatment period (P,0.005). Fosinopril also increased the resistance of the mice plasma low density lipoprotein (LDL) to CuSO -induced oxidation, as shown by a 90% reduction in the LDL content of 4 malondialdehyde (MDA) and also by a prolongation of the lag time required for the initiation of LDL oxidation (from 100 min in the placebo-treated mice to more than 240 min in the fosinopril-treated mice; P,0.001). In addition, fosinopril inhibited CuSO -induced 4 oxidation of LDL that was obtained from the aortas of the treated mice, as shown by an 18% and 37% reduction in the LDL content of lipid peroxides and hydroperoxy-cholesterol linoleate, respectively, compared with the placebo-treated mice (P,0.01). A low dosage of fosinopril (5 mg / kg / d) that was still adequate to reduce their plasma ACE activity and LDL propensity to lipid peroxidation was insufficient to lower their blood pressure. This dosage also reduced the aortic lesion size in the apo E deficient mice by 40% (P,0.01).
The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice a a b a c Tony Hayek , Judith Attias , Raymond Coleman , Sergey Brodsky , Jonathan Smith ,
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Introduction the renin-angiotensin-aldosterone system by reducing the levels of Ang II [1] [2] [3] [4] [5] . Clinical studies have demonstrated Angiotensin II (Ang II) is a powerful growth stimulant that ACE inhibitors significantly reduce the morbidity and that can lead to increased cardiac hypertrophy and smooth mortality of patients with myocardial infarction or heart muscle hyperplasia in the vascular wall [1] [2] [3] [4] [5] . Angiotenfailure [1] [2] [3] [4] [5] . They also reduce the incidence of recurrent sin-converting enzyme (ACE) inhibitors act as vasodilatmyocardial infarction and ischemic events in patients with ors, but the most obvious potential benefit is their effect on coronary artery disease [6, 7] . Data from a variety of animal experiments indicate that ACE inhibitors can attenuate the development of atherosclerosis across a wide range of species, including Watanabe heritable hyperApo E deficient mice are suitable for such studies since lipidemic rabbits, cholesterol-fed Cynomolgus monkeys they develop severe hypercholesterolemia on a low fat, low and minipigs [8] [9] [10] [11] [12] . The mechanisms by which ACE cholesterol chow diet [34, 35] , and extensive atheroscleroinhibitors affect atherosclerosis are not well understood, sis with lesions progressing from lipid-laden fatty streaks but it has been postulated that these agents may have to advanced fibroproliferative lesions by age 20-30 weeks multiple effects, including blood pressure lowering [8, 9] , [36, 37] . We have shown previously [22] that in these mice an antiproliferative effect on vascular smooth muscle cells accelerated atherosclerosis is associated with increased [3] , inhibiting platelet aggregation [13] , decrement of lipid peroxidation. plasminogen activator inhibitor-1 (PAI-1) [14] and the Thus, the aim of this study was to evaluate the respecattenuation of LDL oxidation [15, 16] .
tive roles of blood pressure reduction, LDL oxidation Studies in humans and in animal models have shown inhibition and ACE inhibition on the attenuation of that oxidative modification of LDL plays a crucial role in atherosclerosis by fosinopril or losartan in apo E deficient the build-up of the atherosclerotic lesions, leading to mice. coronary artery disease [17] [18] [19] [20] [21] [22] [23] . We have previously shown that Ang II stimulates macrophage lipid peroxidation, and by so doing, can lead to enhanced cell-mediated 2. Methods oxidation of LDL, resulting in the formation of atherogenic oxidized LDL [24, 25] . We have also shown that LDL The ACE inhibitor, fosinopril, was kindly provided by derived from hypertensive patients is more susceptible to Bristol-Myers Squibb (BMS, Princeton, New Jersey, lipid peroxidation than LDL derived from normotensive USA). The angiotensin II receptor antagonist losartan was controls [26] and that ACE inhibitors significantly atkindly provided by Dr. Ronald Smith, Merck, Sharp and tenuate the propensity of LDL to oxidation [15] . Dohme (MSD, Whitehouse Station, New Jersey, USA). Recently, we demonstrated that the ACE inhibitor, Apo E deficient mice were created by gene targeting in captopril, which contains a sulfhydryl group, attenuated the mouse embryonic stem (ES) cells as previously described 0 progression of atherosclerosis in E mice and this effect [34, 35] . In these mice, apo E deficiency causes severe was associated with a significant inhibition of plasma LDL hypercholesterolemia on chow diet, primarily due to oxidation [16] . In that study, the contribution of blood elevated levels of very low and intermediate density pressure-lowering on the attenuation of atherosclerosis was lipoprotein. not assessed.
Several studies have shown that the antiatherosclerotic 2.1. Experiment 1: High dose of fosinopril effect of ACE inhibitors could be dissociated from their blood pressure-lowering ability [12, 27, 28] . On the other At 8 weeks of age, apo E deficient mice were assigned hand, it was recently shown that in hypertensive rats, a randomly to placebo or to high dose fosinopril groups. high dosage of the ACE inhibitor ramipril increased the Treatment consisted of 25 mg / kg / d of fosinopril as a lifespan more than a low dose which was without an supplement in the drinking water. Mice (20 in each group) antihypertensive effect [29] . Thus, the contribution of were supplemented with the drug for 12 weeks. blood pressure-lowering to the antiatherogenic effect of the ACE inhibitors is still controversial. At the end of the treatment period, blood was collected strated that a high dose of losartan (25 mg / kg / d) atin all groups of mice from the retroorbital plexus under tenuated the progression of atherosclerosis in apo E anesthesia with ether [22] into Eppendorf tubes with 1 deficient mice and this was associated with a significant mmol / l Na EDTA. Plasma cholesterol was determined 2 inhibition of plasma LDL oxidation [33] . enzymatically [22] and serum ACE activity was assayed according to Holmquist et al. [38] . This method measures phometric studies of atherosclerotic lesion development. the reduction in the absorbance at 340 nm which results Thus, the aortic arch was dissected free from the surroundfrom ACE-induced hydrolysis of furylacryloylphenyling fatty tissue and the first 4 mm of the ascending aorta glycemic (FAPGG) to furylacryloylhemylalanine (FAP) (beginning with the aortic valves) removed and cut transand glycylglycine.
versely with razor blades into four blocks of¯1 mm each. LDL (d51.006-1.063 g / ml) was isolated from 3 ml of The samples were kept in the fixative overnight prior to pooled plasma from each group, by sequential density rinsing and storage in 0.1 mol / l sodium cacodylate buffer ultracentrifugation as previously described [22] . The LDL containing 7.5% wt / vol. sucrose. This step was followed protein content was determined by the method of Lowry et by treatment with 1% aqueous solution of osmium tetroxal. [39] .
ide for 4 h, cacodylate rinse, dehydration in ethanol and propylene oxide, and embedding in epoxy resin (Eponate 2.2.1. LDL oxidation 12, Pelco). Transverse sections (1 mm) were cut for light LDL was dialyzed overnight against phosphate buffered microscopy. The prolonged osmium treatment stains the saline (PBS) to remove the EDTA before oxidation. LDL intraluminal, intramural, and intracellular lipid a dense derived from the different groups was diluted with EDTAblack color. Osmium staining 'en bloc' is an excellent free PBS to a final concentration of 100 mg of protein per method for lipids and, without further staining, shows up ml and then incubated in the presence or absence of 10 the atherosclerotic lesions in thin epoxy-embedded sections mM CuSO at 378C for 3 h. At the end of the incubation, at much higher resolution than oil red O staining in frozen 4 the oxidative state of plasma LDL was assayed by desections [16] . Moreover, the sections can be cut on the termination of the thiobarbituric acid reactive substance ultramicrotome and stained with alkaline toluidine blue to (TBARS) assay [40] . In addition, the lag time and the provide even better resolution [16] . kinetics of LDL oxidation were determined by monitoring 'Atherosclerotic lesion' was defined as the area of the formation of conjugated dienes after the supple-(abnormal) pathological structure change. Lesional areas mentation of freshly prepared CuSO (10 mmol / l) by were determined by using a computerized quantitative 4 monitoring the increase in absorbance at 234 nm, observed image-analysis system (Cue-2, Olympus) with appropriate at room temperature (23 8C) every 10 min for a period of 3 morphometric software. The imaging system consists of a h [41] .
Zeiss Universal R photomicroscope (310 objective) fitted with a Panasonic WV-CD50 video camera and 14-inch 2.
Blood pressure
Sony color monitor and IBM-compatible PC. Image analyBlood pressure measurements were performed, using a sis was performed on aortic arches from placebo-treated tail cuff, before and at the end of the treatment period in all mice and mice treated with hydralazine, fosinopril and animals [42] . Computerized blood pressure measuring was losartan. Approximately 80 transverse sections (0.05 mm performed using the IITC model 31 (IITC / Life Science separation) were taken in total from each animal, and of Instruments, USA). Animals were put in a special holder those, sections with atherosclerotic lesions were selected for mice several minutes before beginning the test (to and marked for image analysis. prevent temperature stress, the holder was preheated to
In the present study, standardized 'windows' (fields of 2 368C before placing the animals in the holder). The mouse measurement) with an area of 176 758 mm were used as tail was placed into a device with rubber cuff and follows: placebo mice, hydralazine, fosinopril and losartan. photoelectric sensor. The blood pressure was measured
The results were pooled for each group and presented as using special computer software (Blood Pressure Software, average cross-sectional lesion area per experimental group. IITC, Model 31). The results were displayed as data plots
In order to study the oxidizability of LDL derived from and the summary of digital values (systolic, diastolic and the aortic lesions, mice treated with high dose fosinopril or mean blood pressure) was shown on a computer screen placebo were sacrificed (another ten from each group), (Intel Pentium 100). All measurements were repeated four aortas dissected, placed in cold (48C) PBS and processed times for each animal.
on the same day. Aortic tissues were rinsed several times in cold PBS. Lipoproteins were gently extracted as previ-2.2.3. Analysis of aortic atherosclerotic lesions ously described [16, 33] . One gram of wet tissue (ten mice) At the end of the experimental period, mice were was placed in tubes containing 5 ml of 150 mM NaCl, 0.01 sacrificed, ten from the high dose fosinopril and ten from M phosphate buffer, pH57.4 ('extraction buffer') and the placebo groups. The heart and entire aorta were rapidly incubated overnight at 48C, with gentle agitation. To dissected out and fixed in 3% glutaraldehyde in 0.1 mol / l prevent in vitro LDL modification, the following comsodium cacodylate buffer (pH57.4) with 0.01% calcium pounds were added to the extraction buffer: 0.01% sodium chloride at room temperature. Since it was shown that the azide, 0.05% glutathione, 0.08% benzamidine and 0.01% aortic origin region with the valves and bifurcation is the Na EDTA. At the end of incubation, the medium superna-2 most susceptible for atherosclerosis [34] [35] [36] [37] , we restricted tant was collected after centrifugation at 10 0003g for 15 our study to the aortic arch for comparative histomormin. This supernatant was further centrifuged in a SW41 rotor at 40 0003g for 30 min at 108C. The pellet was discarded and the rest of the solution was used for density gradient ultracentrifugation. The density of this supernatant was adjusted to 1.250 g / ml by the addition of KBr. A 6-ml sample was placed in a tube and overlayered with 6 ml of lipoprotein extraction buffer (d51.0 g / ml). After 48 h of centrifugation at 48C, using SW41 rotor, four visualized bands were separated. These lipoprotein bands were located by their light scattering under indirect illumination, and LDL fractions (d51.020-1.050 g / ml) were collected by gentle pipetting. A 50-ml lipid extract of lesioned LDL in acetone was analyzed by reversed-phase HPLC using an RP-8 column (4325 mm, 5-mm particle size, Merck 3.1.1. Plasma ACE activity and cholesterol levels 3.1.3. LDL oxidation Plasma ACE activity was 768628 m / l in the placeboAfter 12 weeks of treatment, the susceptibility of the treated group and was substantially reduced by fosinopril mice LDL to lipid peroxidation following its incubation to 180691 m / l. Plasma cholesterol in the placebo-treated with 10 mM CuSO was significantly reduced in the apo E 4 0 E mice was 893656 mg / dl and was not significantly deficient mice that were treated with fosinopril compared affected by the administration of fosinopril (906634 mg / with the placebo-treated group, as shown by a 90% dl).
reduction in the LDL MDA content (P,0.001) (Fig. 3A) . Kinetic analysis of LDL oxidation was also performed 3.1.2. Blood pressure and atherosclerosis by continuously monitoring the formation of LDL conjuAt a dose of 25 mg / kg / d, fosinopril reduced the mean gated dienes at 234 nm after the addition of 10 mM CuSO 4 blood pressure from 9362 mmHg before treatment to to the LDL (100 mg of protein per ml) that was derived 7062 mmHg at the end of the treatment period (P, from the different treated groups. After 12 weeks of 0.005). In the placebo group, blood pressure was 8963 treatment, the lag time required for the initiation of mmHg before treatment and did not change significantly at CuSO -induced LDL oxidation was 100 min for LDL 4 the end of the treatment period (9163 mmHg) (Fig. 1A) . derived from the placebo-treated group. In contrast, in the Fosinopril administration for 12 weeks led to a signififosinopril-treated group, no LDL oxidation was observed cant decrease in the development of atherosclerotic lesions even after 240 min of incubation (P,0.001) (Fig. 3B) . and the average lesion area was significantly lower in the Furthermore, the maximal oxidation of LDL at 240 min of (Figs. 1B, 2) .
It is suggested that LDL oxidation takes place mainly in (Fig. 3A) . The two different LDLs were also incubated fosinopril treatment. The open sections are stained alkaline toluidine blue.
for 4 h in the presence of 10 mM CuSO and the absorbance was Both micrographs to the same magnification. 4 monitored every 10 min at 234 nm. The lag time and the kinetics of the LDLs were determined as described in the Methods section (Fig. 3B) . The results represent the mean6SD of three different experiments, each the arterial wall. Thus, we also analyzed the effect of performed in duplicate. *** P,0.001.
fosinopril on the basal oxidative state of LDL-like particles that were isolated from the mice aortic lesions. The content affected by a low dose of losartan (790628 m / l), or of total peroxides in these LDL-like particles was 17% hydralazine (780636 m /l). lower in the fosinopril-treated mice in comparison with LDL-like particles from the aortic lesions of placebo 3.2.2. Blood pressure and atherosclerosis treated mice (P,0.01) (49.462 and 59.865 nmol / mg of In the placebo-, fosinopril-and losartan-treated groups, LDL protein, respectively). Furthermore, we demonstrated mean blood pressure levels before treatment were 9163 a 37% lower LDL-like particle content of cholesteryl mmHg, 8964 mmHg and 9063 mmHg, respectively, and linoleate hydroperoxides in the fosinopril-treated group did not change significantly at the end of the treatment compared with the placebo group (P,0.01) (23.562 and period (Fig. 4A) . As an added control, we used hydralazine 36.963 nmol / mg of LDL protein, respectively).
at a dose of 5 mg / kg / d which reduced blood pressure from 9264 mmHg before treatment to 7864 mmHg at the end of the treatment period (P,0.005) (Fig. 4A ).
Effect of low dosages of fosinopril or losartan on
Fosinopril and losartan, at this low dosage, led to a blood pressure, LDL oxidation and on the progression of significant decrease in the development of atherosclerotic atherosclerosis in apo E deficient mice Apo E deficient mice at the age of 4 weeks were treated Table 1 with a low dose of fosinopril (5 mg / kg / d), a low dose of content of MDA, respectively. Hydralazine had no significant effect on LDL oxidation (Fig. 6A) . Kinetic analysis of LDL oxidation with a low dose of fosinopril or losartan demonstrated a similar antioxidative effect as a high dose of fosinopril or losartan. After 10 weeks of treatment, the lag time for the initiation of CuSO -induced LDL oxidation was observed after 100 4 min for LDL derived from the placebo-treated group; whereas in the low dose fosinopril-or losartan-treated groups, no oxidation was observed up to 150 min (P, 0.001) (Fig. 6B) . Hydralazine had no significant effect on the lag time required for LDL oxidation, compared with the placebo group (Fig. 6B) .
Discussion
The present study demonstrates that the ACE inhibitor, fosinopril, significantly attenuates the development of atherosclerotic lesions in apo E deficient mice. This effect was associated with a significant reduction in plasma ACE activity, the propensity of their plasma and lesional LDL to oxidative modification and blood pressure.
Previous studies that assessed the potential preventive On the other hand, in the dent effects such as vasoconstriction, macrophage foam hydralazine-treated group the lesion area was increased not cell formation, smooth muscle cell proliferation, enhanced 2 significantly to 37 10064714 mm , in spite of significant monocyte adhesion to endothelial cells, inhibition of blood pressure reduction by this drug (Figs. 4B, 5) . macrophage migration and increased oxidative stress [3] [4] [5] 15, 46] . In the aortic arch of hamsters, the presence of ACE mRNA and protein in endothelial cells, intimal 3.2.3. LDL oxidation macrophages and medial smooth muscle cells suggests that The susceptibility of LDL obtained from the apo E Ang II production occurs within the atheroma and this deficient mice to undergo lipid peroxidation was detervasoactive peptide may directly promote the progression of mined in mice treated with a low dose of fosinopril, a low the disease [12] . Therefore, reducing Ang II production dose of losartan or with hydralazine. After 10 weeks of with ACE inhibitors may decrease monocyte recruitment treatment, the susceptibility of the mice LDL to lipid to the arterial wall and reduce foam cell formation. oxidation following its incubation with CuSO was sigIn parallel to the attenuation of atherosclerosis, fosinop-4 nificantly reduced in the apo E deficient mice that were ril significantly reduced the susceptibility of the mouse treated with low dose fosinopril or low dose losartan, in plasma LDL to oxidative modification, as shown by a comparison with the placebo group, as shown by a 90% significant reduction in the LDL-associated TBARS, as and 50% reduction (P,0.001 and P,0.005) in the LDL well as by prolongation of the lag time required for the initiation of LDL oxidation. Since studies in humans and endothelium-dependent relaxation, increased smooth musanimal models have shown that the oxidative modification cle cell proliferation and connective tissue deposition [53-of LDL plays a crucial role in the build-up of the 55]. Despite these known effects of elevated blood presatherosclerotic lesions, leading to coronary artery disease sure on the arterial wall, little is known regarding the [17] [18] [19] [20] [21] [22] [23] , the inhibition of LDL oxidation by fosinopril influence of the reduction of blood pressure on arterial may contribute to the attenuation of atherosclerosis. Furresponses to hypercholesterolemia. thermore, since LDL oxidation takes place mainly in the In order to determine whether the antiatherosclerotic arterial wall [47] , the inhibitory effect of fosinopril on the effects of ACE inhibitors could be dissociated from their oxidative state of LDL-like particles that were isolated blood pressure lowering effect, apo E deficient mice were from the mouse aortic lesions further suggests a direct treated with a low dose of fosinopril that was still adequate effect of the drug on arterial wall Ang II production and to reduce plasma ACE activity and LDL propensity to lipid LDL oxidation. We have shown previously that other peroxidation but was insufficient to lower blood pressure. antioxidants such as vitamin E may have an anWe found that low dose of fosinopril also inhibited the 0 tiatherogenic effect in E mice [48] . On the other hand, in progression of atherosclerosis in apo E deficient mice, humans the efficacy of vitamin E as antiatherogenic was although to a lesser extent than a high dose of fosinopril demonstrated only in the 'CHAOS' trial [49] by using a (where significant blood pressure lowering was observed). high-dose of vitamin E (400 IU daily). Other antioxidants However, a significant reduction of blood pressure by such as b-carotene were not proven to be useful in hydralazine was not accompanied by an attenuation of prevention of atherosclerosis. atherosclerosis in our model. Similar to our present A high dose of fosinopril also significantly reduced the findings, recent studies in cholesterol-fed rabbits given blood pressure in apo E deficient mice. This effect may enalapril [27] and hamsters treated with captopril [12] have also contribute to the inhibition of atherosclerosis.
suggested that the protection against atherosclerosis by Hypertension is recognized as a potent promoter of ACE inhibitors in these models may be independent of atherosclerosis in humans [50] as well as in hypercholesblood pressure lowering. terolemic animals [51] . Epidemiologic data have shown
In contrast to the present findings, Chobanian et al. [56] that human subjects with low blood pressure also have low demonstrated that a low dose of the ACE inhibitor, rates of clinical complication of atherosclerosis [52] . Many trandolapril, which has no influence on blood pressure, had of the arterial changes induced by hypertension mimic no effect on atherosclerosis in WHHL rabbits. The reason those caused by hypercholesterolemia, including impaired for the apparent difference in the results is unclear and the apo E deficient mice, although to a lesser extent than a high dose of losartan, as shown previously [33] . Taken together, our data suggest that the antiatherosclerotic effects of fosinopril (and of losartan) in apo E deficient mice are due not only to blood pressure reduction but also to a direct inhibition of Ang II actions in the arterial wall, including inhibition of LDL lipid peroxidation.
Recently, we have demonstrated that a high dose of However, losartan also increases plasma renin and Ang II have an antiproliferative effect and may contribute to the 
